Ki67 labelling index: An independent predictor of progression in prostate cancer treated by radical prostatectomy

Journal of Pathology

Volumn 178, Issue 4, 1996, Pages 437-441

  Bubendorf, Lukas ^a   Sauter, Guido ^a   Moch, Holger ^a   Schmid, Hans Peter ^a   Gasser, Thomas C ^a   Jordan, Paul ^a   Mihatsch, Michael J ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Differentiation; Ki67; Neuroendocrine; Prognosis; Progression; Proliferation; Prostate cancer

Indexed keywords

MONOCLONAL ANTIBODY KI 67;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NEUROSECRETORY CELL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROSTATECTOMY;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CELL DIFFERENTIATION; CELL DIVISION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEUROENDOCRINE TUMORS; NUCLEAR PROTEINS; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0029983124     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199604)178:4<437::AID-PATH484>3.0.CO;2-4     Document Type: Article

References (35)

1. Muir CS, Nectoux J, Staszewski J The epidemiology of prostatic cancer. Geographical distribution and time-trends. Acta Oncol 1991; 30: 133-140.
2. Murphy GP, Whitmore WF. A report of the workshops on the current status of the histologic grading of prostate cancer. Cancer 1979, 44: 1490-1494.
3. Mostofi MK, Sesterhenn IA. Davis CCJ Prostatic carcinoma: problems in the interpretation of prostatic biopsies. Hum Pathol 1992, 23: 223-241.
4. Visakorpi T, Kalliomemi OP, Paronen IYI, Isola JJ. Heikkinen AI, Korvula TA. Flow cytometric analysis, of DNA ploidy and S-phase fraction from prostatic carcinomas- implications for prognosis and response for endocrine therapy Br J Cancer 1991; 64: 578-582.
5. Visakorpi T. Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prostatic carcinoma J Pathol 1992, 168: 7-13.
6. Harper ME, Glynne JE. Goddard L, et al Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters. Prostate 1992; 20: 243-253.
7. Harper ME, Goddard L, Wilson DW. et al. Pathological and clinical associations of Ki-67 defined growth fractions in human prostatic carcinoma. Prostate 1992, 21: 75-84.
8. Vesalainen SL, Lipponen PK., Talja MT, Alhava EM, Syrjanen KJ. Proliferating cell nuclear antigen and p53 expression as prognostic factors in TI 2MO prostatic adenocarcinoma. In J Cancer 1994; 58: 303-308
9. Aprikian AC, Cordon CC, Fair WR, Reuter VE. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma Cancer 1993; 71: 3952-3965.
10. Di Sant'Agnese PA. Neuroendocrine differentiation in human prostatic carcinoma Hum Pathol 1992, 23: 287-296
11. Bonkhoff H, Wernert N, Dhom G, Remberger K Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate 1991; 19: 91-98
12. Datige MC, Delmas V. APUD type endocrine tumour of the prostate Incidence and prognosis in association with adenocarcinoma. In: Murphy GP, Khoury S, Küss R, eds. Prostate Cancer, Part A Research, Endocrine Treatment, and Histopathology. New York: Alan R. Liss, 1987; 529-531.
13. Cohen RJ, Glezerson G, Haffejee Z. Neuro-endocrine cells - a new prognostic parameter in prostate cancer. Br J Urol 1991; 68: 258-262.
14. Cohen MK. Arber DA, Coffield KS, Keegan GT. McClintock J. Speights VO Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression. Cancer 1994: 74: 1899-1903.
15. UICC. Classification of Malignant Tumours 4th edn. 2nd revision Berlin Springer-Verlag, 1992
16. Gleason DF. Histologic grading of prostatic carcinoma In: Roth LM, ed. Pathology of the Prostate New York- Churchill Livingstone, 1990; 83-93.
17. Moch H, Sauter G, Epper R, Mihatsch M, Gudat F. Waldmann F. p53 but not erb-B2 expression is associated with rapid tumor cell proliferation in urinary bladder cancer Hum Pathol 1994; 25: 1346-1351.
18. Vesalainen S, Lipponen P, Talja M, Syrianen K. Mitotic activity and prognosis in prostatic adenocarcinoma Prostate 1995; 26: 80-86.
19. Gerdes J, Lemke H, Baisch H, Wacher HH, Stein H. Cell cycle analysis of a cell proliferation-associated nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984, 133: 1710-1715
20. Limas C, Frizelle SP. Proliferative activity in benign and neoplastic prostatic epithelium J Pathol 1994, 174: 201-208.
21. Cher ML, Chew K, Rosenau W, Carroll PR. Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression. Prostate 1995; 26: 87-93.
22. Cattoretti G, Becker M, Key G. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paiaffin sections. J Pathol 1992; 168: 357-363
23. Raymond WA, Leong AS, Bolt JW, Milios J, Jose JS. Growth fractions in human prostatic carcinoma determined by Ki-67 immunostaining J Pathol 1988, 156: 161-167
24. Gallee MP, Visser-De JE, Ten Kate FJW, Schroeder FH, Van Der Kwast TH. Monoclonal antibody Ki-67 defined growth fraction in benign prostatic hyperplasia and prostatic cancer. J Urol 1989; 142: 1342-1346.
25. Sadi MV, Barrack ER. Determination of growth fraction in advanced prostate cancer by Ki-67 immunostaining and its relationship to the time to tumor progression after hormonal therapy. Cancer 1991, 67: 3065-3071.
26. Thompson SJ, Mellon K, Charlton G, Marsh C, Robinson M, Neal DF. p53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. Br J Ural 1992, 69: 609-613
27. McLoughlin J, Foster CS, Price P, Williams G, Abel PD. Evaluation of Ki-67 monoclonal antibody as prognostic indicator for prostatic carcinoma. Br J Urol 1993; 72: 92-97
28. Linden MD, Torres FX, Kubus J, Zarbo RJ. Clinical application of morphologic and immunocytochemical assessments of cell proliferation. AJCP 1992; 5 (Suppl 1): S4-S13.
29. Azzopardi JG, Evans DJ. Argentaffin cells in prostatic carcinoma: differentiation from lipofuscin and melanin in prostatic epithelium. J Pathol 1971; 104: 247-251
30. Abrahamsson PA, Alumets J, Falkmer S, Grimelius L. Peptide-hormoneand serotonin-immunoreactive tumour cells in carcinoma of the prostate. Pathol Res Pract 1987, 182: 298-307
31. Bologna M, Festuccia C, Muzi P, Biord L, Ciomei M Bombesin stimulates growth of human prostatic cancer cells in vitro Cancer 1989; 63: 1714-1720.
32. Abrahamsson PA, Falkmer S, Falt K Grimelius L. The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker". Puthol Res Pract 1989; 185: 373-380.
33. Stratton M, Evans DJ, Lampert JA Prostatic adenocarcinoma evolving into carcinoid; selective effect of hormonal treatment J Clin Pathol 1986; 39: 750-756.
34. Bonkhoff H, Stein U, Remberger K. Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate. Virchows Arch A [Pathol Anat Histopathol] 1993, 423: 291-294
35. Kadmon D, Thompson TC, Lynch GR, Scardino PT. Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol 1991, 146: 358-361.